Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800730 | 0.96 | KDR (0.53) | KDRTLR7SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL6803952 | 0.84 | KDR (0.51) | KDRTLR7SMN1; SMN2AKT1RPS6KB1 | |
| SCHEMBL807666 | 0.83 | CYP2C19 (0.58) | SMN1; SMN2HTTCYP2C19ADKKMO | |
| SCHEMBL807662 | 0.80 | TSHR (0.48) | SMN1; SMN2HTTCYP2C19AKT1 | |
| SCHEMBL30662621 | 0.80 | MKNK1 (0.46) | KDRTLR7AKT1MAPTRPS6KB1 | |
| SCHEMBL28406969 | 0.80 | MKNK1 (0.46) | KDRTLR7AKT1MAPTRPS6KB1 | |
| SCHEMBL5889032 | 0.78 | TSHR (0.54) | TLR7SMN1; SMN2KMOMAPT | |
| SCHEMBL30828973 | 0.78 | CYP2C19 (0.53) | SMN1; SMN2HTTCYP2C19ADKKMO | |
| SCHEMBL26647473 | 0.78 | CYP2C19 (0.53) | SMN1; SMN2HTTCYP2C19ADKKMO | |
| SCHEMBL2075530 | 0.76 | KIT (0.48) | TLR7SMN1; SMN2HTTAKT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885TLR7 1151/4885SMN1; SMN2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.